TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03160092

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention
Description: The intervention aims to:~* Support the participant to explore their unusual experiences~* Reduce the distress or anxiety participants feel in response to their unusual experiences, through:~  * Helping them to recognise how common these unusual experience~ * Supporting them to make sense of their unusual experiences~ * Supporting them to understand why they may be experiencing these symptoms~ * Challenging any unhelpful beliefs they hold about their symptoms~* Help the participant to recognise the triggers to their unusual experiences~* Support the participant to increase their activities and socialisation~The intervention is not aiming to 'get rid' of the participant's symptoms, but to reduce their distress in response to them, which may result in improved wellbeing and reduced symptoms.
Study: NCT03214016

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Exercise
Description: 1 hour of aerobic training on a treadmill, 3 times a week, during 8 weeks.
Study: NCT02813239

Intervention type: OTHER
Intervention: hCG + GnRH agonist
Description: Oocyte maturation with hCG + GnRH agonist
Study: NCT01552863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: One capsule of 40 mg PF-00345439 Formulation A, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: One capsule of 40 mg PF-00345439 Formulation E, single dose
Study: NCT02765204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucose
Study: NCT03529435

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Massed Prolonged Exposure
Description: Participants will complete fifteen weekday 90-minute Prolonged Exposure therapy sessions over three consecutive weeks. If necessary, the treatment window may be extended for another week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Outpatient Prolonged Exposure
Description: The IOP-PE will include the same primary treatment components as the Massed-PE protocol (fifteen weekday 90-minute PE sessions delivered five days a week over a three-week period) plus eight augmentations designed to maximize treatment outcomes. Similar to the Mass-PE, participants will have three consecutive weeks to complete treatment; however, the treatment window may be extended another week if necessary.
Study: NCT04812977

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group A
Description: Combination of intravitreal triamcinolone acetonide (Kenacort-AⓇ) (2mg/0.05ml) and intravitreal bevacizumab (Avastin®) (1.25mg/0.05ml)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group A
Description: Combination of intravitreal triamcinolone acetonide (Kenacort-AⓇ) (2mg/0.05ml) and intravitreal bevacizumab (Avastin®) (1.25mg/0.05ml)
Study: NCT02107235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral rigosertib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Study: NCT02420509

Intervention type: DRUG
Intervention: systemic chemotherapy
Description: twelve months of 5-FU or capecitabine with bevacizumab starting 4-8 weeks after surgery
Study: NCT02449902

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol
Description: 1 10 µg capsule inserted vaginally for 14 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1 placebo capsule inserted vaginally for 14 days.
Study: NCT00641797

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meclizine
Description: medication administration 25mg PO one time

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Epley Maneuver
Description: Patient has vestibular rehabilitation utilizing the Epley Maneuver.
Study: NCT03214016

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates
Description: 1 hour of Mat Pilates, 2 times a week, during 8 weeks.
Study: NCT01811004

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: miraDry
Description: miraDry
Study: NCT01552863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: One capsule of 40 mg PF-00345439 Formulation F, single dose
Study: NCT01811004

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nd:YAG Laser
Description: Nd:YAG 1440 nm Laser

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nd:YAG Laser
Description: Nd:YAG 1440 nm Laser

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nd:YAG Laser
Description: Nd:YAG 1440 nm Laser

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Botox®
Description: Botox®
Study: NCT00133965

Intervention type: BEHAVIORAL
Intervention: Standard Palliative Care
Description: If you are in the Standard Palliative Care group you will receive the standard care that is usually provided here at Memorial Hospital. This can include services such as consultations by physicians, nurses and other healthcare professionals. In addition, referrals to community resources and services can also be made. The study period will be between five and seven days. At the beginning and at the end of the study, you will be asked to fill out a series of questionnaires as described above. Total time commitment for this study should be approximately 60-90 minutes.
Study: NCT02336321

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BNCI controlled hand exoskeleton
Description: The BNCI system fuses and translates bio-signals related to user intention into control signals of an assistive device performing grasping motions
Study: NCT02405182

Intervention type: OTHER
Intervention: Magnetic Resonance Imaging

Intervention type: OTHER
Intervention: Magnetic Resonance Imaging
Study: NCT00739713

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sea buckthorn (Hippophaë rhamnoides) oil
Description: Dosage 2 g/d, frequency twice/d, duration 3 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparison
Description: Placebo comparison, dosage 2 g/d, frequency twice/d, duration 3 months
Study: NCT03402061

Intervention type: DIETARY_SUPPLEMENT
Intervention: nutrient enhanced recipes
Description: normal ingredients will be substituted to promote nutrient density of products

Intervention type: DIETARY_SUPPLEMENT
Intervention: nutrient enhanced recipes
Description: normal ingredients will be substituted to promote nutrient density of products

Intervention type: DIETARY_SUPPLEMENT
Intervention: nutrient enhanced recipes
Description: normal ingredients will be substituted to promote nutrient density of products
Study: NCT03080025

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBCT® (Cognitively Based Compassion-Training)
Description: The CBCT® (Cognitively Based Compassion-Training) as a secular approach was established as a structured protocol.~The therapeutic tools are based on systemic approaches \& techniques, which contains a resource- \& solution orientation and the approach of Gottman's model of healthy relationships (e.g. trust and commitment - based on that - elements like the positive perspective).~Four dyadic exercises are introduced to enhance positive reciprocity between the romantic partners (based on concepts of couple communication training):~a) Building mindful ability to talk, b) building mindful ability to listen (without reacting initially), c) appreciation in action - indulging the partner, d) noticing, how the partner is doing something good for me - gratefulness in action verbally/non-verbally. Finally, the empathy exercise has been added inspired by CBASP therapy for chronic major depression.
Study: NCT02135614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Presatovir
Description: Presatovir 200 mg (4 x 50 mg tablets) administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Presatovir placebo
Description: Presatovir placebo tablets administered orally
Study: NCT02142608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR55
Description: Ultrasound contrast agent
Study: NCT01634841

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Walnuts
Description: 30 to 60g (1 to 2 oz) per day of walnuts

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: habitual diet
Description: Dietary information will be provided
Study: NCT04579354

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: virtual reality tour
Description: Patients will be guided via VR on their way through the hospital to the operating theater
Study: NCT00946738

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Biofeedback
Description: Biofeedback training as behaviour treatment was performed thrice weekly for 4 week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Deep oscillation
Description: Deep oscillation providing a pulsing electromagnetic field was performed thrice weekly for 4 weeks.
Study: NCT00957827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: keflex
Description: keflex 500 mg BID 5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo BID for five days
Study: NCT05732324

Intervention type: PROCEDURE
Intervention: IVUS guided PCI optimization
Description: PCI to long lesion will be optimized according to the IVUS.
Study: NCT02484937

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group 2 (PCP Treatment)
Description: For the PCP group treatment will be performed (pain treatment/medications) by the Primary Care Physician in his/her office/clinic.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group 1 (PMS Treatment)
Description: For the PMS group treatment will be performed (pain treatment/medications) by the Pain Medicine Specialist in his/her office/clinic.
Study: NCT05732324

Intervention type: PROCEDURE
Intervention: FFR guided PCI optimization
Description: PCI to long lesion will be optimized according to the FFR.

Intervention type: DIAGNOSTIC_TEST
Intervention: FFR measurement
Description: Fractional flow reserve protocol will be applied for both FFR-guided and IVUS-guided PCI groups. FFR will be measured according to the standard practice using intravenous adenosine. FFR will be recorded before PCI at the distal third of the coronary artery and after PCI at the same location. In FFR optimization group more than one post PCI FFR measurements could be acquired if the operators performed additional optimization. In IVUS optimization group only one post PCI FFR measurement will be recorded after which the procedure will be considered to be finished, and no further interventions will be undertaken. The same FFR measurements will be performed at 9-12 months follow-up.

Intervention type: DIAGNOSTIC_TEST
Intervention: FFR measurement
Description: Fractional flow reserve protocol will be applied for both FFR-guided and IVUS-guided PCI groups. FFR will be measured according to the standard practice using intravenous adenosine. FFR will be recorded before PCI at the distal third of the coronary artery and after PCI at the same location. In FFR optimization group more than one post PCI FFR measurements could be acquired if the operators performed additional optimization. In IVUS optimization group only one post PCI FFR measurement will be recorded after which the procedure will be considered to be finished, and no further interventions will be undertaken. The same FFR measurements will be performed at 9-12 months follow-up.
Study: NCT04170725

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient and Healthy Volunteers training protocol
Description: Patients and Healthy Volunteers will undergo a 14-day endurance training protocol. No study drugs will be administered. Patients and Healthy Volunteers will be instructed regarding their training protocol. Training sessions will be undertaken on days 1, 3, 5, 7, 9 and 11 after the first examination day. Patients and Healthy Volunteers will be asked to contract their TA muscle repeatedly by pulling the right foot towards the head in a standing position while the heel remains on the ground (at 5 second intervals). In order to carry out the training they will also receive a video demonstrating the exercise. On days 1 and 3 they will do the exercise for 5 minutes, on days 5 and 7 for 10 minutes and on days 9 and 11 for 15 minutes.
Study: NCT01053143

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A/H1N1 pandemic influenza vaccine (non- adjuvanted)
Description: 0.5 mL, Intramuscular
Study: NCT00081276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triapine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT04785547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: 15 mcg/m2/day for 28 days
Study: NCT02352467

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aurix
Description: Aurix is a platelet-rich plasma gel used in the treatment of non-healing wounds. It will be administered twice weekly for 2 weeks then weekly.
Study: NCT04451148

Intervention type: OTHER
Intervention: Obese with or without metabolic syndromesubjects
Description: Children with obesity and with or without metabolic syndrome

Intervention type: OTHER
Intervention: Obese with or without metabolic syndromesubjects
Description: Children with obesity and with or without metabolic syndrome
Study: NCT00825760

Intervention type: DRUG
Group type: OTHER
Intervention: Topical PPA904 gel and light

Intervention type: DRUG
Group type: OTHER
Intervention: Topical PPA904 gel and light

Intervention type: DRUG
Group type: OTHER
Intervention: Topical placebo gel plus light

Intervention type: DRUG
Group type: OTHER
Intervention: Topical placebo gel plus light
Study: NCT00815464

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Liquid Acupuncture (Herb Acupoint Injection)
Description: Each 4 weeks per one circle.The first 3 weeks for treatment practice(one per week)and the last week for test collection.
Study: NCT03435887

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Alere q HIV-1/2 Detect for point of care infant testing
Description: The investigators will pilot the Alere q HIV-1/2 Detect mobile system for point of care (POC) infant testing at two of the study hospitals. A blood sample will be collected from each HIV-exposed infants at birth (before discharge from Maternity or at first follow-up MCH visit within 14 days postnatal) and at 6-week EID visit (4-8 weeks postnatal) for analysis with Alere q HIV-1/2 Detect, with results available within 1-2 hours to enable mother notification at the same clinic visit.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: GeneXpert HIV-1 Qual for point of care infant testing
Description: The investigators will pilot the GeneXpert HIV-1 Qual mobile system for point of care (POC) infant testing at two of the study hospitals. A blood sample will be collected from each HIV-exposed infants at birth (before discharge from Maternity or at first follow-up MCH visit within 14 days postnatal) and at 6-week EID visit (4 to \<24 weeks postnatal) for analysis with GeneXpert HIV-1 Qual, with results available within 1-2 hours to enable mother notification at the same clinic visit.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HIV DNA PCR testing (Standard of Care)
Description: This is the standard of care for infant HIV testing. A dried blood spot sample will be collected from the infant and shipped to a central laboratory for HIV DNA PCR testing. Results will then be returned to the hospital.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HIV DNA PCR testing (Standard of Care)
Description: This is the standard of care for infant HIV testing. A dried blood spot sample will be collected from the infant and shipped to a central laboratory for HIV DNA PCR testing. Results will then be returned to the hospital.
Study: NCT00728234

Intervention type: DEVICE
Intervention: aEEG recording
Description: weekly recordings with aEEG
Study: NCT01358214

Intervention type: BEHAVIORAL
Intervention: Questionnaire on Quality of Life.
Description: The impact of a disease on patient's Quality of Life has meanwhile gained more influences on the choice of treatment alternatives. The benefit of a method is currently not only defined by the objective outcome but also influenced by the Quality of Life. Two questionnaires with 20 respectively 40 Questions should be filled in by the patients.

Intervention type: BEHAVIORAL
Intervention: Questionnaire on Quality of Life.
Description: The impact of a disease on patient's Quality of Life has meanwhile gained more influences on the choice of treatment alternatives. The benefit of a method is currently not only defined by the objective outcome but also influenced by the Quality of Life. Two questionnaires with 20 respectively 40 Questions should be filled in by the patients.

Intervention type: BEHAVIORAL
Intervention: Questionnaire on Quality of Life.
Description: The impact of a disease on patient's Quality of Life has meanwhile gained more influences on the choice of treatment alternatives. The benefit of a method is currently not only defined by the objective outcome but also influenced by the Quality of Life. Two questionnaires with 20 respectively 40 Questions should be filled in by the patients.
Study: NCT00100828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Study: NCT03395288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-Mannose
Description: A total of 2 g D-mannose daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-Mannose
Description: A total of 2 g D-mannose daily
Study: NCT04935541

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine infusion
Description: After Dexmedetomidine infusion was given for 10 minutes, local anesthesia was applied by the surgeon. Peribulbar block and periorbital infiltration application were performed by applying a mixture of lidocaine (Jetokain, Adeka, Turkey) and 1/200000 adrenaline. After the local anesthetic agent was applied by the surgeon, orbital compression was provided for 5 minutes with maximum pressure to block the eyelid movements. Cataract surgery procedures of all patients included in the study were performed by the same surgeon.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil infusion
Description: After Remifentanil infusion was given for 10 minutes, local anesthesia was applied by the surgeon. Peribulbar block and periorbital infiltration application were performed by applying a mixture of lidocaine (Jetokain, Adeka, Turkey) and 1/200000 adrenaline. After the local anesthetic agent was applied by the surgeon, orbital compression was provided for 5 minutes with maximum pressure to block the eyelid movements. Cataract surgery procedures of all patients included in the study were performed by the same surgeon.
Study: NCT00241670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-aminolevulinic acid (5-ALA)
Description: 1.5 grams 5-ALA dissolved in 50 ml water, single dose, orally, 2-4 hours prior to surgery
Study: NCT00771498

Intervention type: DRUG
Group type: OTHER
Intervention: Lopinavir
Description: ARV treatment: 2 NRTIs + lopinavir/r 800mg / 200 mg (4 tablets of Kaletra) every 12 hours, daily and orally Antituberculosis treatment: rifampin (600 mg/daily) + isoniazide (400 mg/daily) for 6 months, both in fasting condition + pirazinamide (2000 mg) for the first two months
Study: NCT01213966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OZ439
Description: po, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OZ439
Description: po, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OZ439
Description: po, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OZ439
Description: po, single dose
Study: NCT02166255

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: siRNA-transfected peripheral blood mononuclear cells APN401
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01895777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabigatran etexilate
Description: Age and weight appropriate capsule dose (combination of 50 mg, 75 mg and 110 mg capsules) or pellets or oral liquid formulation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard of care
Description: Low molecular weight heparin, vitamin K antagonist or fondaparinux prescribed in an open label fashion for 3 months (these medications will not supplied in this study as IMP)
Study: NCT00214383

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHESS Internet telehealth
Description: CHESS Internet telehealth
Study: NCT03348878

Intervention type: OTHER
Group type: OTHER
Intervention: assessment of drug compliance
Description: assessment of drug compliance using electronic monitoring devices (2 months duration)
Study: NCT01709500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LMT (atorvastatin, simvastatin, or rosuvastatin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alirocumab
Description: Alirocumab administered as a subcutaneous (SC) injection of 1 mL into the abdomen, thigh, or outer area of the upper arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to alirocumab administered as a SC injection of 1 mL into the abdomen, thigh, or outer area of the upper arm.
Study: NCT03765450

Intervention type: DRUG
Intervention: Infliximab
Description: Patients will receive infliximab at the discretion of their physician as part of standard of care.
Study: NCT02303912

Intervention type: DRUG
Group type: OTHER
Intervention: Nuc-1031 and Carboplatin
Description: Nuc-1031 IV injection on day 1 and day 8 repeated every 21 days Carboplatin IV infusion on day 1 repeated every 21 days (Total 6 cycles)
Study: NCT00721071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypertonic Saline
Description: After each subject has performed post-bronchodilator spirometry, he/she will inhale increasing concentrations of 3, 4, and 5% of hypertonic saline for 7 minutes each for 3 cycles until expectorating a sufficient sputum sample.
Study: NCT02780258

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane Silk
Study: NCT03860974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serratus Plane block (single injection)
Description: A single-injection serratus plane block will be administered using ropivacaine 0.5% with epinephrine 1:200,000-400,000 (20 mL of local anesthetic for unilateral surgery; 16 mL of local anesthetic each side for bilateral surgery).